Velká Británie - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

recordati rare diseases uk ltd - dactinomycin - powder for solution for injection - 500microgram

Filipíny - angličtina - FDA (Food And Drug Administration)

qualimed pharma, inc.; distributor: qualimed pharma, inc. - dactinomycin - lyophilized powder for injection (i.v.) - 500 mcg

Keňa - angličtina - Pharmacy and Poisons Board

veteran pharmaceuticals limited p o box 63575 nairobi - dactinomycin - injection - 0.5mg per vial - cytotoxic antibioticsand related substances:

Irsko - angličtina - HPRA (Health Products Regulatory Authority)

lundbeck pharmaceuticals ireland - dactinomycin - pdr for soln for injection - 0.5 milligram

Indie - angličtina - Central Drugs Standard Control Organization

merind - dactinomycin - inj - 500mcg - 1

Indie - angličtina - Central Drugs Standard Control Organization

celon(vivilon) - dactinomycin - inj - 0.5mg - 1

Indie - angličtina - Central Drugs Standard Control Organization

vhb - dactinomycin - inj - 500mcg - v.

Indie - angličtina - Central Drugs Standard Control Organization

ch.bhagat - dactinomycin - vial - 0.5mg/2ml - vial

Spojené státy - angličtina - NLM (National Library of Medicine)

sandoz inc - methotrexate sodium (unii: 3ig1e710zn) (methotrexate - unii:yl5fz2y5u1) - methotrexate 25 mg in 1 ml - methotrexate is indicated in the treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole. in acute lymphocytic leukemia, methotrexate is indicated in the prophylaxis of meningeal leukemia and is used in maintenance therapy in combination with other chemotherapeutic agents. methotrexate is also indicated in the treatment of meningeal leukemia. methotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides (cutaneous t cell lymphoma), and lung cancer, particularly squamous cell and small cell types. methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-hodgkin's lymphomas. methotrexate in high doses followed by leucovorin rescue in combination with other chemotherapeutic agents is effective in prolonging relapse-free survival in patients with non-metastatic osteosarcoma who have undergone surgical resection

Spojené státy - angličtina - NLM (National Library of Medicine)

eisai inc. - palonosetron hydrochloride (unii: 23310d4i19) (palonosetron - unii:5d06587d6r) - palonosetron 0.25 mg in 5 ml - aloxi is indicated for: - moderately emetogenic cancer chemotherapy -- prevention of acute and delayed nausea and vomiting associated with initial and repeat courses - highly emetogenic cancer chemotherapy -- prevention of acute nausea and vomiting associated with initial and repeat courses aloxi is indicated for prevention of acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy. aloxi is indicated for prevention of postoperative nausea and vomiting (ponv) for up to 24 hours following surgery. efficacy beyond 24 hours has not been demonstrated. as with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. in patients where nausea and vomiting must be avoided during the postoperative period, aloxi is recommended even where the incidence of postoperative nausea and/or vomiting is low. aloxi is contraindicat